Moderna mRNA flu vaccine beats standard shot, awaits FDA review

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

Moderna: mRNA Vaccine Is Only Viable In A COVID-Like Situation, Strong Sell

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
Reuters

Moderna COVID-19 vaccine appears to work as well in older adults in early study

(Reuters) - Moderna Inc said on Wednesday its experimental COVID-19 vaccine induced immune responses in older adults similar to those in younger participants, offering hope that it will be effective ...

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to ...
Morningstar

Moderna's work developing seasonal vaccines is 'risky' under current FDA, analyst says

The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development As COVID-19 vaccine sales dwindle, pressure on Moderna to grow its business has increased.

Hantavirus stirs vaccine skeptics, Moderna questions, prediction conspiracy

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
AOL

FDA refuses to review Moderna’s application for mRNA flu vaccine, company says

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...